A blood-cancer treatment that Stanford researchers have spent more than two decades developing has now reached an important milestone. Its first commercial patient has been treated following U.S. Food and Drug Administration approval. According to the Stanford Cancer Institute, the therapy, known as Orca-T, was given to a patient at Stanford Medicine outside a clinical trial. The treatment received FDA approval in June 2026 after a phase 3 trial found that 78% of patients receiving Orca-T were free from moderate-to-severe graft-versus-host disease (GVHD) one year after transplantation. Among patients who received a standard transplant, the figure was 38.4%.
Why GVHD remains a concern
For people with blood cancers, a stem cell transplant can offer a chance to rebuild the blood and immune system with healthy cells from a donor. But the procedure also carries serious risks, including GVHD. The condition occurs when immune cells from the donor recognise the patient’s tissues as foreign and begin attacking them. GVHD can affect different parts of the body and can become a significant complication following transplantation.At the same time, donor immune cells have an important role in fighting cancer. This creates a difficult balance for doctors: they want the new immune system to help eliminate cancer cells without causing excessive damage to healthy tissue. Orca-T was developed with that problem in mind.
A different approach to donor cells
In a conventional transplant, different types of donor cells are generally delivered together. Orca-T takes a more controlled approach. The treatment separates the cells and gives them to the patient in a specific sequence. It begins with stem and early blood-forming cells. Patients then receive regulatory T cells, or Tregs, which play a role in controlling immune responses. Several days later, mature immune cells are administered.The thinking behind the approach is relatively straightforward: if the different cell populations can be carefully controlled, doctors may be able to support blood and immune-system recovery while reducing the immune reaction responsible for GVHD. The treatment is the result of research at Stanford that stretches back more than 20 years. Researchers spent years studying Treg cells and their potential role in making donor stem cell transplantation safer.
What the clinical trial showed
The results from a phase 3 clinical trial became an important part of the treatment’s path towards approval. One year after transplantation, 78% of patients who received Orca-T were free from moderate-to-severe GVHD. That compared with 38.4% of patients who underwent standard transplantation, according to the Stanford Cancer Institute.The findings helped support the FDA’s approval of Tregzi, the approved form of Orca-T, in June 2026. Stanford said the treatment became the first Treg cell-based immunotherapy approved by the FDA for clinical use. The difference seen in the trial is significant because GVHD can be one of the most difficult complications following a donor stem cell transplant. A treatment that can lower the risk of moderate-to-severe GVHD could therefore change how some patients experience the recovery period following transplantation.
First commercial patient treated
The first commercial patient to receive Orca-T at Stanford has high-risk leukemia. According to Stanford, the patient was interested in the therapy partly because it requires less chemotherapy and has a lower side-effect profile. The treatment was administered as an approved therapy rather than as part of a clinical trial. For the researchers involved, the treatment represents a major moment after years of work. Robert Negrin, a Stanford Cancer Institute member and former chief of the Blood and Marrow Transplantation & Cellular Therapy Division, was among those involved in the research and development of the therapy. Stanford said some of Negrin’s first discoveries related to Orca-T were published more than two decades ago. What began as laboratory research has since moved through clinical development and testing before reaching patients as an FDA-approved treatment.
Research continues after approval
FDA approval does not mark the end of Stanford’s work on Orca-T. Researchers are continuing to study how the therapy could be used in other groups of patients and in combination with other treatments. Recent and ongoing research includes a completed trial involving older patients, work looking at Orca-T alongside CAR-T cell therapy and trials involving people who do not have matched donors. These studies could help determine how widely the approach can eventually be used.For now, the treatment’s first commercial use marks the culmination of a research effort that began more than 20 years ago. Orca-T has moved from an idea explored in the laboratory to a treatment that can be given to eligible patients with blood cancers. The early trial results also point to why the approach attracted attention: one year after transplantation, 78% of patients receiving Orca-T were free from moderate-to-severe GVHD, compared with 38.4% after standard transplantation. For patients facing the risks of a stem cell transplant, reducing that complication could be an important part of making treatment safer.
About The Author
